ReviewCanadian journal of gastroenterology & hepatology2026
Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers.
Review in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers.Canadian journal of gastroenterology & hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although there are various treatment modalities available for hepatocellular carcinoma (HCC), HCC is still among the most common causes of cancer-related death globally. Identifying independent biomarkers of poor prognosis in HCC patients remains a critical goal to allow timely intervention and ameliorate patient survival. MicroRNAs (miRNAs), the most widely investigated small noncoding RNAs to date, play a crucial role in regulating the initiation and progression of HCC. The expression of numerous miRNAs is altered in tumor tissues and blood specimens of HCC patients, underscoring their potential as promising prognostic biomarkers. This review offers an exhaustive overview of the current literature examining tissue- and circulation-derived miRNAs as single or combined independent prognostic biomarkers in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.